Phathom Pharmaceuticals announced positive results from a Phase 3 trial showing VOQUEZNA provided rapid and sustained relief of nighttime GERD symptoms. Patients experienced increased heartburn-free nights and improved sleep over 24 weeks. Nighttime GERD affects up to 80% of patients and can lead to complications. The trial involved 772 patients and found that VOQUEZNA was generally well-tolerated. The drug is a potassium-competitive acid blocker approved for various GERD indications. Researchers believe the results highlight the potential of VOQUEZNA to address unmet needs in GERD treatment, especially for nighttime symptoms.

Read more at GlobeNewswire: Phathom Pharmaceuticals Announces Publication of Data from